Freenome CEO Mike Nolan said Freenome’s progress in developing its cancer liquid biopsy, coupled with Roche’s expertise in detecting cancer via molecular diagnostics, as well as treating it via drugs, helped unite the companies and positions them for further success starting this year. Based in South San Francisco, CA, Freenome has developed a machine learning-enabled multiomics blood-based test for early detection of colorectal cancer (CRC) and advanced adenomas, considered to be clinically relevant precursors of CRC . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post Blood Stake: Roche Raises Freenome Investment to $360M appeared first on GEN – Genetic Engineering and Biotechnology News.

Source